Amgen VP-Licensing Scott Foraker: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Roche’s Mircera has not impacted Amgen’s aggressiveness on pursuing deals, Foraker says.
Roche’s Mircera has not impacted Amgen’s aggressiveness on pursuing deals, Foraker says.